Member Info for MickTKipper

AVON...........Avon Rubber On the verge of a breakout. http://uk.advfn.com/p.php?pid=staticchart&s=L%5EAVON&p=4&t=46

19 Nov 2014 Avon Rubber PLC AVON WH Ireland Securities Buy 671.25 659.50 800.00 825.00 Retains

Avon Rubber operating profits up 19 November 2014 | 07:45am StockMarketWire.com - Avon Rubber's revenue for the year to the end of September was flat at £124.8m (2013: £124.9m) but increased 5% on a constant currency basis. Operating profit before depreciation and amortisation (EBITDA) rose 14% to £22.9m (2013: £20.0m) and operating profit rose 20% to £17.0m (2013: £14.2m) (an increase of 26% at constant currency). The progressive strengthening of sterling during the year gave the group a foreign exchange translation headwind. The US $/£ average rate was $1.65 (2013: $1.56) and this 9 cent headwind was equivalent to £5.7m at a revenue level and £0.8m at an operating profit level. Chief executive Peter Slabbert said: "2014 has been an excellent year reflecting the strategic decisions made over the last three years to invest in innovative new products and technologies while expanding our international markets. This strategy will continue to drive growth in the years ahead." - See more at: http://www.stockmarketwire.com/article/4926141/Avon-Rubber-operating-profits-up.html#sthash.d5kADz82.dpuf

19 Nov 2014 Avon Rubber PLC AVON Investec Buy 672.50 659.50 720.00 800.00 Retains

19 Nov 2014 Pace PLC PIC JP Morgan Cazenove Overweight 0.00 340.10 445.00 441.00 Reiterates

19 Nov 2014 Prudential PLC PRU Deutsche Bank Buy 1,480.25 1,491.00 1,630.00 1,680.00 Reiterates

19 Nov 2014 Pace PLC PIC Exane BNP Paribas Outperform 0.00 340.10 530.00 530.00 Reiterates

19 Nov 2014 Avon Rubber PLC AVON N+1 Singer Buy 0.00 659.50 750.00 760.00 Reiterates

AVON Beats consensus forecasts easily on adjusted pre tax and EPS.

David Buik ‏@truemagic68 15m15 minutes ago Scotland Panmure's Paul Jones posts a 'BUY' recommendation for LAVENDON GROUP

CannacordBuy Target: 600p Valuation Shares are now trading at an unjustified discount to peers, in our view. Shares have fallen 22% over the last two months and now trade at large discounts to peers (Bloomberg FY2 EV/EBITDA: Optimal 7.8x, Safecharge 13.2x, Wirecard 14.3x, UK payment processors subsector 14.2x). Despite its low multiples, we expect Optimal to grow EBITDA 30% compared to 27% for Safecharge, 25% for Wirecard and 18% for the UK payment processors subsector. Share performance catalyst We expect a strong full year trading update.

Good blog on the stock here...... http://wheeliedealer.weebly.com/blog/my-rationale-for-buying-optimal-payments-opay

LAND... LAND SECURITIES excelent trading update tues saw stock move to a 6 year high and breakout, VOL is heavy having broken out from a long term horizontal range. Momentum behind these at the moment. https://pbs.twimg.com/media/B2TwxaxIYAA835t.jpg"

Chart again.... http://content.screencast.com/users/thomaser/folders/Default/media/26aaccd9-16e6-48ff-bfd3-2e657842f606/tht%2012.jpg

Chart again http://content.screencast.com/users/thomaser/folders/Default/media/26aaccd9-16e6-48

THT THONTONS PLC ...looks no reason why it cant go on and replicate last years upward action going into XMAS Mothers Day and Easter. Looking to take out resistance at 134p 148p 160p and previous top of 165p. Recent increase in volume and MACD positive. http://chartattack.webs.com/tht%201.jpg <b>FUNDIES</b> Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield 29-Jun-13 221.05 4.29 5.31p 17.4 0.2 +101% n/a 0.0% Historical P/E of 17 to june 2013. Thorntons PLC FORECASTS 2015 2016 Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p) N+1 Singer 12-11-14 BUY 10.68 10.90 13.97 14.40 Investec Securities 07-11-14 BUY 9.40 9.68 11.80 12.15 Charles Stanley Securities [R] 15-01-14 BUY 9.80 10.45 13.20 13.98 GROWTH 2014 (A) 2015 (E) 2016 (E) Norm. EPS 111.97% 11.13% 29.36% DPS % % % INVESTMENT RATIOS 2014 (A) 2015 (E) 2016 (E) EBITDA £18.40m £20.62m £23.79m EBIT £10.95m £m £m Dividend Yield 0.00% % % Dividend Cover x x x <b>PER 12.98x 11.68x 9.03x</b> PEG 0.12f 1.05f 0.31f Net Asset Value PS 24.16p 38.70p 55.20p First Quarter Interim Statement. <a href="http://www.investegate.co.uk/thorntons-plc--tht-/rns/trading-statement/201410130700070494U/">http://www.investegate.co.uk/thorntons-plc--tht-/rns/trading-statement/201410130700070494U/</a>

<b>BTG says long – awaited varicose vein treatment has positive debut</b> 11 Nov 2014 - 09:19 (Adds CEO comments, shares) Nov 11 (Reuters) – British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts. Varithena, which has taken 18 years to reach the market after BTG acquired the technology, is an injectable foam that dissolves varicose veins rather than traditional techniques of stripping. "The first commercial treatment was in August," Chief Executive Louise Makin said on Tuesday. "The feedback from the physicians about the patients has been very good. We are very encouraged by that and everything is on track." She said the size of market for procedures reimbursed by insurers – for moderate to serious varicose veins – was about $250 million a year. BTG was seeking approval to treat veins that were unsightly, but not yet painful, a market worth an additional $250 million, she said. BTG, which also makes anti-venom drugs and products that deliver oncology drugs, posted a 25 percent rise in first-half revenue to 191.2 million pounds ($303 million), and a 15 percent rise in pretax profit to 37.6 million pounds. The company said it expected its full-year revenue to be around the top end of its guidance of 330 million to 345 million pounds, despite adverse foreign exchange impacts. Its shares were up 0.5 percent at 744 pence at 0851 GMT.

<b>BRIEF BTG posts rise in H1 profit, sees full – year revenue at top end</b> 11 Nov 2014 - 07:42 Nov 11 (Reuters) – BTG Plc H1 revenue rose 25 percent to 191.2 million stg Operating profit increased to £42.8m (h1 13/14: £25.0m) Profit before tax £37.6m (h1 13/14: £32.7m) Overall, we are in a good position to deliver our organic growth plans Source text for Eikon: ... Further company coverage: BTG.L

Broker Views on CSRT........ Consort Medical PLC FORECASTS 2015 2016 Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p) Edison 06-11-14 None 17.94 41.28 18.11 18.91 43.21 18.11 Peel Hunt LLP 06-11-14 BUY 22.62 37.99 19.02 33.78 47.65 19.96 N+1 Singer [D] 06-11-14 HOLD 22.37 35.90 17.90 32.54 45.40 17.90 Arden Partners 06-11-14 BUY 22.80 45.01 18.11 33.30 53.63 19.50 Shore Capital 31-10-14 BUY 18.40 46.18 18.11 20.00 49.68 18.11 FinnCap 31-10-14 HOLD 22.00 39.80 20.70 32.10 51.40 20.70 Westhouse Securities 30-10-14 BUY Canaccord Genuity Ltd 09-10-14 BUY 22.26 37.40 14.34 33.34 46.56 18.11 Numis Securities Ltd 01-10-14 HOLD 18.60 45.48 18.11 20.20 49.33 18.11 Investec Securities 04-09-14 BUY 18.30 52.14 20.70 19.60 55.83 20.70

CSRT CONSORT MEDICAL,lovely tech set up here, results in about a month. Investech set 986p target Canaccord 996p target. https://pbs.twimg.com/media/B1x4bCcCcAA3u4J.jpg IG...............Client sentiment 100% of IG client accounts with open positions in this market expect the price to rise. 0% of IG client accounts with open positions in this market expect the price to fall.